Swipe Left For English News
中国上海，
2023年6月19日
全球领先的合同研究、开发和生产CRDMO服务公司药明生物（WuXi Biologics,2269.HK）宣布加入“科学碳目标倡议”（Science Based Targets initiative，简称SBTi），并提交了科学碳目标承诺书。这也标志着药明生物成为最早加入SBTi的生物药CRDMO公司之一，身体力行，为应对全球气候变化发挥表率作用。
SBTi是由全球环境信息研究中心（CDP）、世界资源研究所（WRI）、联合国全球契约组织（UNGC）以及世界自然基金会（WWF）联合发起的倡议，旨在定义和推广科学碳减排目标设定。根据倡议要求，药明生物将于两年内设定温室气体减排近期目标、及2050年前达成净零排放的远期目标，并向SBTi提交认证，以推动实现《巴黎协定》中“将全球平均温度升幅限制在工业化前水平以上1.5℃以内”的目标。
陈智胜博士
首席执行官
ESG委员会主席
药明生物
面对全球气候变化挑战，药明生物作为全球领先的生物药CRDMO企业，责无旁贷。我们积极制定相关政策和制度，建立碳专项工作组，将节能减碳落实到全球各基地业务运营中，同时提升气候相关治理、战略、风险和绩效指标等信息披露透明度。此次加入SBTi也是药明生物减碳战略的重要组成部分，开启了公司科学减碳的新征程。未来，我们将按照SBTi要求积极制定科学碳目标和减排行动计划，不断加大脱碳力度，为推动全球可持续发展贡献积极力量。
在日常运营中，药明生物积极推进节能减碳项目实施，探索推广可再生能源的应用。目前公司爱尔兰敦多克生物制药基地已实现100%可再生电力供应，中国无锡马山和上海奉贤基地的屋顶光伏也已投入使用。为进一步推动全球各基地挖掘节能减排潜力，公司于近期发布《药明生物节能白皮书》，坚持绿色可持续发展理念，助力减碳目标早日达成。自设立2030年温室气体（范围一和范围二）排放密度下降50%的环境目标以来，公司在2022年已实现了27%的降低（相比2020年基数），并将不断落实可持续发展承诺。
推荐阅读
新闻速递 | 前沿洞见 | 精彩活动
点击视频，了解更多药明生物ESG战略
关于药明生物
药明生物（股票代码：2269.HK）是一家全球领先的合同研究、开发和生产（CRDMO）服务公司。公司通过开放式、一体化生物制药能力和技术赋能平台，提供全方位的端到端服务，帮助合作伙伴发现、开发及生产生物药，实现从概念到商业化生产的全过程，加速全球生物药研发进程，降低研发成本，造福病患。
药明生物在中国、美国、爱尔兰、德国和新加坡拥有超过12000名员工。通过药明生物人的专业服务团队，以及先进技术和精深洞见，公司为客户提供高效经济的生物药解决方案。截至2022年12月底，药明生物帮助客户研发和生产的综合项目高达588个，其中包括17个商业化生产项目。
药明生物将环境、社会和治理（ESG）视为业务发展和企业精神的重要组成部分，并致力于成为全球生物药CRDMO领域的ESG领导者，例如应用更绿色环保的新一代生物制药技术和能源等引领行业发展。公司成立了由首席执行官领导的ESG委员会，全面落实ESG战略并践行可持续性发展承诺。
更多信息，请访问：www.wuxibiologics.com
媒体关系 PR@wuxibiologics.com
业务垂询 info@wuxibiologics.com
WuXi Biologics Commits to Science Based Targets Initiative, a New Milestone in Its Net-Zero Journey
Shanghai, China,
June 19, 2023
WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced its signing of the Science Based Targets initiative's (SBTi) commitment letter, making it leading biologics CRDMO company to join the SBTi with concrete actions in combating climate changes.
The SBTi is a collaboration between CDP, the World Resources Institute, the UN Global Compact, and Worldwide Fund for Nature to clearly define and promote the development of science-based targets for carbon emission reductions.
In accordance with SBTi criteria and recommendations, WuXi Biologics will develop its near-term science-based emission reduction targets and long-term targets to reach net-zero greenhouse gas (GHG) emissions by 2050. WuXi Biologics' targets will be in alignment with the SBTi as well as the Paris Agreement, which pursues efforts to limit global warming to 1.5°C above pre-industrial levels.
Dr. Chris Chen
CEO
ESG Committee Chairman
WuXi Biologics
To tackle climate challenges, we as a global leading CRDMO have adopted vigorous measures, including formulating climate change policies and establishing a dedicated carbon taskforce, to embed energy conservation and carbon reduction into our global business operations. In addition, we have been improving the disclosure transparency of climate related governance, strategies, risks and performance. Committing to the SBTi is an important component of WuXi Biologics' carbon strategy, and also marks a new starting point of our carbon action journey. Going forward, we will actively develop science-based carbon targets and emission reduction action plans in accordance with SBTi, and continuously increase our efforts to Net-Zero while advancing global sustainability.
The company has already begun implementing energy saving projects and exploring more renewable energy use. Its Dundalk site in Ireland receives 100% of its electricity supply from renewable sources, while rooftop photovoltaics have been put into operation in China at its Mashan site in Wuxi city and its Fengxian site in Shanghai. To further promote energy conservation and emission reduction at global sites, the company is to release its Energy Saving White Paper, advocating sustainable development and contributing to the achievement of its carbon reduction target. It has achieved a 27% decrease of GHG emission (scope 1 and scope 2) from 2020 to 2022, contributing significantly to its goal of achieving a 50% decrease in GHG emission intensity by 2030.
About WuXi Biologics
WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.
With over 12,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of December 31, 2022, WuXi Biologics is supporting 588 integrated client projects, including 17 in commercial manufacturing.
WuXi Biologics views Environmental, Social, and Governance (ESG) responsibilities as an integral component of our ethos and business strategy, and we aim to become an ESG leader in the biologics CRDMO sector. Our facilities use next-generation biomanufacturing technologies and clean-energy sources. We have also established an ESG committee led by our CEO to steer the comprehensive ESG strategy and its implementation, enhancing our commitment to sustainability.
For more information about WuXi Biologics, please visit: www.wuxibiologics.com
Media
PR@wuxibiologics.com
Business
info@wuxibiologics.com
注：本信息不构成药明生物的信息披露或投资建议
